Loading...
•
Mar 31, 2023
Spyre Q1 2023 Earnings Report
Aeglea BioTherapeutics reported financial results for the first quarter of 2023.
Key Takeaways
Aeglea BioTherapeutics reported a net loss of $18.4 million and revenue of $0.2 million for the first quarter of 2023. The company had $39.8 million in cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023.
Cash and cash equivalents, marketable securities, and restricted cash totaled $39.8 million as of March 31, 2023.
Revenue for the first quarter of 2023 was $0.2 million.
Research and development expenses for the first quarter of 2023 were $13.8 million.
Net loss for the first quarter of 2023 was $18.4 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...